These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24798290)

  • 1. Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.
    Dutta NK; Pinn ML; Karakousis PC
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4048-53. PubMed ID: 24798290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
    Dutta NK; Pinn ML; Karakousis PC
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5567-9. PubMed ID: 24936590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis.
    Dutta NK; Pinn ML; Zhao M; Rudek MA; Karakousis PC
    J Antimicrob Chemother; 2013 Jun; 68(6):1327-30. PubMed ID: 23463208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use".
    Amaral L; Molnar J
    Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):109-14. PubMed ID: 20156179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
    Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
    Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.
    Musuka S; Srivastava S; Siyambalapitiyage Dona CW; Meek C; Leff R; Pasipanodya J; Gumbo T
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5870-7. PubMed ID: 24041886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis.
    Singh A; Sharma S
    Tuberculosis (Edinb); 2014 Dec; 94(6):695-700. PubMed ID: 25305001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
    Srivastava S; Sherman C; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reliability of rifampicin resistance as a proxy for multidrug-resistant tuberculosis: a systematic review of studies from Iran.
    Nasiri MJ; Zamani S; Pormohammad A; Feizabadi MM; Aslani HR; Amin M; Halabian R; Imani Fooladi AA
    Eur J Clin Microbiol Infect Dis; 2018 Jan; 37(1):9-14. PubMed ID: 28823010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of isoniazid-resistant pulmonary tuberculosis.
    Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Lim SY; Lim SY; Koh WJ
    BMC Infect Dis; 2008 Jan; 8():6. PubMed ID: 18211720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis.
    van Soolingen D; Hernandez-Pando R; Orozco H; Aguilar D; Magis-Escurra C; Amaral L; van Ingen J; Boeree MJ
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.
    Abebe G; Abdissa K; Abdissa A; Apers L; Agonafir M; de-Jong BC; Colebunders R
    BMC Res Notes; 2012 May; 5():225. PubMed ID: 22574696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
    Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
    J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.